Pharmacologic classification: interleukin-1 blocker
Therapeutic classification: immunosuppressant
Pregnancy risk category: C
AVAILABLE FORMS
Single-use vial: 220 mg
INDICATIONS AND DOSAGES
Cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS)--
Adults: Loading dose of 320 mg, administered as two 160-mg (2-ml) subcutaneous injections given at different sites; then 160 mg (2 ml) subcutaneous injections once weekly.
Children age 12 to 17: Loading dose of 4.4 mg/kg up to a maximum of 320 mg subcutaneously, given at divided sites if necessary; then once weekly injections of 2.2 mg/kg up to a maximum 160 mg.
CONTRAINDICATIONS AND CAUTIONS
Contraindicated in those hypersensitive to drug.
Use caution in presence of infection and in pregnant or breast-feeding patients.
INTERACTIONS
Drug-drug.
Other interleukin blockers (anakinra) or tumor necrosis factor blockers (etanercept, adalimumab, infliximab) or corticosteroids: May increase the risk of serious infection. Avoid using together.
ADVERSE REACTIONS
CNS: hypoesthesia.
GI: nausea, diarrhea, stomach discomfort.
GU: UTI.
Hematologic: hyperlipidemia.
Respiratory: upper respiratory infection, sinusitis, cough.
Other: injection site reactions, immunosuppression.
Reactions may be common, uncommon, life-threatening,
or COMMON AND LIFE-THREATENING.
|
rilonacept